Requires insurance coverage of epinephrine for persons aged 18 or younger when medically necessary.
Impact
The implications of A1908 are significant for healthcare policy in New Jersey, as it sets a precedent for how insurance companies manage the approval and coverage of necessary medical devices for minors. By eliminating prior authorization requirements, the bill simplifies access to essential health tools for children, thus potentially improving emergency response times in serious medical situations. Additionally, it could alleviate the financial burden on families, ensuring that cost does not deter access to life-saving treatments.
Summary
A1908, sponsored by Assemblywoman Ellen J. Park, is a bill introduced in New Jersey that mandates health insurance coverage for the purchase of epinephrine auto-injector devices for individuals aged 18 or younger. This measure aims to ensure that children who require these critical medical devices, often used for severe allergic reactions, have access without the burden of prior authorization or other utilization management requirements. The bill stipulates that various types of health insurance plans, including hospital service corporations and health maintenance organizations, must provide this coverage when it is deemed medically necessary and prescribed by a healthcare provider.
Contention
While the bill seeks to bolster health protections for young individuals, the assurance of coverage without prior authorization may raise concerns among insurance providers regarding cost management and prevention of misuse. Some stakeholders might argue that without checks, there could be increased demand or claims for epinephrine devices even in noncritical situations. Debates surrounding the balance of access versus regulation of medical services are expected as the bill progresses through legislative discussions.
Requires health insurers to cover colorectal cancer screenings for covered persons aged 33 or over and covered persons under the age of 33 if deemed medically necessary.
Requires health insurers to cover colorectal cancer screenings for covered persons aged 33 or over and covered persons under the age of 33 if deemed medically necessary.